NDC 71287-220

TECARTUS

Brexucabtagene Autoleucel

TECARTUS is a Intravenous Suspension in the Cellular Therapy category. It is labeled and distributed by Kite Pharma, Inc.. The primary component is Brexucabtagene Autoleucel.

• Product ID: 71287-220_05fdc1a5-d34a-4830-b6d9-c52e7dfb3c63
• NDC: 71287-220
• Product Type: Cellular Therapy
• Proprietary Name: TECARTUS
• Generic Name: Brexucabtagene Autoleucel
• Dosage Form: Suspension
• Route of Administration: INTRAVENOUS
• Marketing Start Date: 2021-10-01
• Marketing Category: BLA /
• Application Number: BLA125703
• Labeler Name: Kite Pharma, Inc.
• Substance Name: BREXUCABTAGENE AUTOLEUCEL
• Active Ingredient Strength: 1000000 1/68mL
• NDC Exclude Flag: N
• Listing Certified Through: 2022-12-31

Packaging

NDC 71287-220-02

1 BAG in 1 PACKAGE (71287-220-02) > 68 mL in 1 BAG (71287-220-01)

• Marketing Start Date: 2021-10-01
• NDC Exclude Flag: N
• Sample Package?: N

Drug Details

NDC Crossover Matching brand name "TECARTUS" or generic name "Brexucabtagene Autoleucel"

NDC	Brand Name	Generic Name
71287-219	TECARTUS	brexucabtagene autoleucel
71287-220	TECARTUS	brexucabtagene autoleucel